Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852525 | 1.00 | KCNH2 (0.46) | KCNH2FFAR4ROCK1ROCK2HTR7 | |
| SCHEMBL19852325 | 0.88 | KCNH2 (0.53) | KCNH2HTR7HTR2AADRA1B | |
| SCHEMBL19838628 | 0.79 | HTR2A (0.41) | KCNH2HTR7HTR2ACCR3 | |
| Hydrochloric Acid SCHEMBL19838581 | 0.78 | HTR2A (0.41) | KCNH2HTR7HTR2ACCR3 | |
| SCHEMBL19852330 | 0.78 | HTR7 (0.45) | KCNH2HTR7HTR2AADRA1B | |
| SCHEMBL9824929 | 0.77 | KCNH2 (0.49) | KCNH2HTR2A | |
| SCHEMBL19852425 | 0.76 | HTR7 (0.42) | KCNH2HTR7HTR2AADRA1BCCR3 | |
| Hydrochloric Acid SCHEMBL10407709 | 0.75 | HTR1A (0.55) | KCNH2HTR7HTR2AADRA1B | |
| SCHEMBL19839340 | 0.72 | HTR2A (0.43) | FFAR4ROCK1ROCK2HTR7HTR2A | |
| SCHEMBL19852517 | 0.72 | HTR2A (0.43) | FFAR4ROCK1ROCK2HTR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | KCNH2 158/4885FFAR4 3733/4885ROCK1 2401/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | KCNH2 158/4885FFAR4 3733/4885ROCK1 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.